Simplicity Wealth LLC Buys New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Simplicity Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,306 shares of the biopharmaceutical company's stock, valued at approximately $483,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $33,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Morton Brown Family Wealth LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $35,000. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $35,000. Finally, Synergy Investment Management LLC purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD traded up $2.75 during mid-day trading on Thursday, hitting $112.05. The stock had a trading volume of 7,023,598 shares, compared to its average volume of 7,745,911. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $139.38 billion, a PE ratio of 302.84, a PEG ratio of 0.71 and a beta of 0.29. The company's fifty day simple moving average is $105.40 and its two-hundred day simple moving average is $101.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The firm's revenue for the quarter was down .3% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Wall Street Analyst Weigh In

Several research firms have issued reports on GILD. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock worth $4,630,310 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.